CureVac reshapes deal with GSK, putting upfront cash toward cancer pipeline

By revamping its deal with GSK and reducing headcount, CureVac is marshaling its resources around cancer vaccines in or nearing the clinic with a cash runway that now extends into 2028.

CureVac N.V. (NASDAQ:CVAC) will receive €400 million ($430.4 million) up front from GSK plc (LSE:GSK; NYSE:GSK) as it hands over full development and commercialization rights to mRNA vaccines to prevent COVID-19 and influenza, including seasonal and avian flu. The revised deal makes CureVac eligible for €1.05 billion in additional milestones, plus royalties. ...